Development and validation of a novel nomogram for predicting overall survival in gastric cancer based on inflammatory markers

Table 1 Baseline demographics and clinical characteristics of patients in the training and validation cohorts, n (%)

Variables	Training cohort (n = 543)	Validation cohort (n = 361)	P value
Pathological types			0.369
Adenocarcinoma	96 (91.3)	336 (93.1)
Signet-ring cell	25 (4.6)	14 (3.9)
Adenosquamous	1 (0.2)	2 (0.6)
Squamous carcinoma	4 (0.7)	4 (1.1)
Mucinous cell	17 (3.1)	5 (1.4)
Macroscopic type			0.932
Borrmann I	22 (4.1)	15 (4.2)
Borrmann II	391 (72.0)	260 (72.0)
Borrmann III	113 (20.8)	72 (19.9)
Borrmann IV	17 (3.1)	14 (3.9)
Tumor location			0.415
Upper	250 (46.1)	156 (43.3)
Middle	123 (22.7)	85 (23.6)
Lower	169 (31.2)	119 (33.1)
Surgery selection			0.344
Distal gastrectomy	117 (21.5)	88 (24.4)
Total gastrectomy	401 (73.8)	261 (72.6)
Proximal gastric resection	25 (4.6)	11 (3.0)
Differentiated grade			0.662
High	25 (4.6)	16 (4.4)
Middle	268 (49.5)	181 (50.2)
Poor	248 (45.9.3)	164 (45.4)
Sex			0.669
Male
Female	142 (26.2)	89 (24.7)
Age			0.925
< 60
≥ 60	334 (61.5)	224 (62)
Neutrophil count	3.17 ± 4.49	2.89 ± 4.06	0.326
Platelet count	196.5 ± 71.70	205.48 ± 84.35	0.086
Lymphocyte count	1.64 ± 1.68	1.58 ± 0.59	0.491